奕瑞科技公告称，公司已完成2021年限制性股票激励计划预留授予部分第三个归属期的归属登记手续， 总股本由2.114117亿股增加至2.11449139亿股。"奕瑞转债"转股价格相应调整为114.97元/股，自2025年 12月22日起生效。"奕瑞转债"于12月19日停止转股，12月22日起恢复转股。该债券发行规模14.35亿 元，期限为2022年10月24日至2028年10月23日。 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-111 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 奕瑞电子科技集团股份有限公司（以下简称"公司"）于 2025 年 12 月 17 日 召开第三届董事会第二十二次会议，审议通过《关于以集中竞价交易方式回购公 司股份方案的议案》，并于 2025 年 12 月 18 日披露了《奕瑞科技关于以集中竞价 交易方式回购公司股份的回购报告书》（公告编号：2025-101）、《奕瑞科技第三 届董事会第二十二次会议决议公告》（公告编号：2025-100）。 二、公司前十名无限售条件股东持股情况 | 序号 | 股东名称 | 总持有数量 | 占无限售条件流 | | --- | --- | --- | --- | | | | （股） | 通股比例（%） | | 1 | 上海奕原禾锐投资咨询有限公司 | 29,452,682 | 14.70 | | 2 | 海南合毅投资有限公司 | 11,721,318 | 5.85 | | 3 | 上海常则管理咨询合伙企业（有限合伙 ...

Group 1 - The core viewpoint of the news is that Yirui Technology's stock has experienced fluctuations, with a current price of 104.52 CNY per share and a market capitalization of 22.097 billion CNY, reflecting a year-to-date increase of 54.67% [1] - As of September 30, 2025, Yirui Technology reported a revenue of 1.549 billion CNY, representing a year-on-year growth of 14.22%, and a net profit attributable to shareholders of 471 million CNY, which is a 20.61% increase compared to the previous year [2] - The company has distributed a total of 789 million CNY in dividends since its A-share listing, with 557 million CNY distributed over the past three years [3] Group 2 - Yirui Technology's main business involves the research, production, sales, and service of digital X-ray detectors, with the sales of detectors accounting for 81.21% of its main revenue [1] - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices, and is involved in sectors such as in vitro diagnostics and precision medicine [1] - As of September 30, 2025, the number of shareholders increased by 14.61% to 8,011, while the average circulating shares per person decreased by 12.74% to 24,992 shares [2]

Group 1 - The medical device sector increased by 0.56% on December 19, with Kangzhong Medical leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] - Notable gainers in the medical device sector included Kangzhong Medical, which rose by 7.36% to a closing price of 44.90, and Rendu Biotech, which increased by 6.78% to 50.40 [1] Group 2 - The medical device sector experienced a net inflow of 3.65 million yuan from institutional investors, while retail investors saw a net inflow of 15 million yuan [2] - Major stocks with significant net inflows included Rejing Bio with 49.71 million yuan and Yuyue Medical with 43.84 million yuan [3] - Conversely, retail investors showed net outflows in several stocks, including Yuyue Medical and Mairui Medical, indicating a mixed sentiment in the market [3]

Group 1 - The core viewpoint of the news is that Yirui Technology's stock has seen a significant increase of 5.02%, reaching a price of 106.66 yuan per share, with a total market capitalization of 22.549 billion yuan [1] - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, specializes in the research, production, sales, and services of digital X-ray detectors [1] - The main revenue composition of Yirui Technology includes 81.21% from detector sales, 7.66% from core component sales, 5.89% from solutions/technical services, 4.57% from accessory sales, and 0.66% from leasing income [1] Group 2 - From the perspective of fund holdings, one fund under Taikang Asset Management has Yirui Technology as a significant investment, holding 41,500 shares, which accounts for 3.99% of the fund's net value, ranking it as the seventh largest holding [2] - The Taikang Medical Health Stock Fund A (015139) was established on March 8, 2022, with a current scale of 76.9785 million yuan, and has experienced a year-to-date loss of 12.75% [2] - The fund manager, Fu Hongzhe, has been in position for nearly 3 years, with the fund's total assets amounting to 311 million yuan, and the best and worst returns during his tenure being 4.69% and -10.79%, respectively [3]

Group 1 - The company announced a share repurchase plan, allowing for the repurchase of shares at a price not exceeding RMB 150.00 per share, with a total fund of no less than RMB 100 million and no more than RMB 200 million within a period of 6 months [1][2] - On December 18, 2025, the company repurchased 79,800 shares, accounting for 0.04% of the total share capital, at a maximum price of RMB 101.68 per share and a minimum price of RMB 100.79 per share, using a total of RMB 8.0786 million [2][3] Group 2 - The company completed the registration of shares for the third vesting period of its 2021 restricted stock incentive plan, with 37,439 shares to be listed on December 23, 2025 [6][8] - The total number of shares after the vesting will remain at 211,449,139 shares, and the new shares will not change the status of the controlling shareholder [19][21] Group 3 - The company adjusted the conversion price of its convertible bonds due to the increase in total share capital, with the new conversion price set at RMB 114.97 per share, effective from December 22, 2025 [23][25] - The adjustment was based on the issuance of 37,439 shares at a price of RMB 62.34 per share, resulting in a conversion price adjustment formula that reflects the increase in share capital [27][28]

Core Viewpoint - The company, Yirui Technology (688301.SH), has initiated its first share buyback on December 18, 2025, through the Shanghai Stock Exchange, indicating a strategic move to enhance shareholder value [1] Group 1: Share Buyback Details - The company repurchased a total of 79,800 shares, which represents 0.04% of its total share capital [1] - The highest price paid for the shares was 101.68 RMB per share, while the lowest price was 100.79 RMB per share [1] - The total amount of funds used for the buyback was 8.0786 million RMB, excluding transaction fees such as stamp duty and commissions [1]

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-110 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 2025 年 12 月 17 日，公司召开第三届董事会第二十二次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司通过上海证券交易所 交易系统以集中竞价交易方式回购公司已发行的人民币普通股（A 股）股票，回 购的股份将在未来适宜时机用于员工持股计划及/或股权激励，回购价格不超过人 民币 150.00 元/股（含），回购资金总额不低于人民币 10,000 万元（含），不超过人 民币 20,000 万元（含），回购期限自董事会审议通过本次回购方案之日起 6 个月内。 具体内容详见公司于 2024 年 12 月 18 日在上海证券交易所网站（www.sse.com.cn） 披露的《奕瑞科技关于以集中竞价交易方式回购公司股份的回购报告书》（公告编 号：2025-101）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司首次 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-108 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 2021 年限制性股票激励计划预留授予部分 第三个归属期的归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 37,439股。 本次股票上市流通总数为37,439股。 本次股票上市流通日期为2025 年 12 月 23 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责 任公司上海分公司（以下简称"中国结算上海分公司"）相关业务规定，奕瑞电子科 技集团股份有限公司（以下简称"公司"）收到中国结算上海分公司近日出具的《证 券变更登记证明》，公司完成了 2021 年限制性股票激励计划（以下简称"本次激励 计划"）预留授予部分第三个归属期的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-109 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于"奕瑞转债"转股价格调整暨转股停牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券停复牌情况：适用 因"奕瑞转债"转股价格调整，本公司的相关证券停复牌情况如下： | 证券代 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌期 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 码 | | | | 间 | | | | 118025 | 奕瑞转债 | 可转债转股停牌 | 2025/12/19 | 全天 | 2025/12/19 | 2025/12/22 | 调整前转股价格：114.98 元/股 调整后转股价格：114.97 元/股 转股价格调整生效日期：2025 年 12 月 22 日 一、转股价格调整依 ...